Complete response to immunotherapy in a metastatic lymphoepithelioma-like bladder carcinoma: a case report

期刊论文
出版模式：

开放获取
发表日期：

2024年11月8日

查看全文

Sara Elena Campos Ramírez,
Sofía Elena Ruffini Egea,
María Luna Monreal Cepero,
Fátima Mocha Campillo,
Pablo Trincado Cobos,
Natalia Pascual de la Fuente,
Luis Gallart Caballero,
Paula Morillas Martínez,
Susana Barriendos Sanz,
Carmen Santander Lobera

摘要

Background

Lymphoepithelioma-like carcinoma of the bladder (LELC-B) is a very rare variant of bladder carcinoma, has a good prognosis, and possibly a high response to platinum-based chemotherapy (ChT) and immune-checkpoint inhibitors (ICI).

Case presentation

This is the case of a male patient that presented a metastatic relapse of a LELC-B, the disease progressed after platinum based first line ChT. Second line with atezolizumab was initiated with progressive tumor shrinking until complete response was achieved. Final atezolizumab discontinuation was decided in agreement with the patient after 3 years of maintenance of complete response.

Conclusion

After the experience of this case and the few cases of neoadjuvant treatment with pembrolizumab of localized disease, it seems that immunotherapy may play a main role in the treatment of this variant of bladder carcinoma.